Shiela Plasencia, director of practice support at the Community Oncology Alliance, shares what she's looking forward to at the 2023 Community Oncology Conference.
Here's what to look forward to at the Community Oncology Alliance (COA) 2023 Community Oncology Conference, which will be held March 22-24, in Kissimee, Florida.
Transcript
What are you looking forward to the most at the COA 2023 Community Oncology Conference?
Seeing everyone! It's just it's still great to be out and be able to network and collaborate. And we've got some great topics coming this year. I think it's going to be super exciting to hear about the different conference sessions. But really, it's great just to see everybody and be in person again.
Are there any speakers or panel topics you're particularly looking forward to, that you would recommend to people attending the conference?
Judy [Alberto, MHA, RPh, BCOP, director of Clinical Initiatives at COA] has got a panel on value-based enterprise that I think is very, very interesting. It's a fairly new topic. I'm really excited about that panel.
And then it's also our 20th anniversary. There's a lot of excitement around that, and a lot of our past presidents will be there.
And just the path that community oncology has taken in the past 20 years, it's just kind of great to reemphasize that, and look and see where we were, what we've gotten to now, and what we have in front of us.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More